Β2-agonist in patients with chronic obstructive pulmonary disease
Abstract
The pathogenesis of chronic obstructive pulmonary disease (COPD) is explained by chronic inflammation leading to bronchial obstruction. The mechanism of COPD determines the key role of bronchodilators in the basic therapy of the disease, among which β2-agonists occupy an important place.
About the Author
N. N. Mescheryakova
Scientific Research Institute of Pulmonology, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
References
1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence and future trends. Lancet, 2007, 370: 765-773.
2. Global Initiative for Chronic Obstructive Luhg Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.org/uploads/users/files/GOLD_ Report_2013_Feb20/pdf
3. Пульмонология. Национальное руководство краткое издание. Под ред. акад. РАМН А.Г Чучалина. М.: «Гэотар-Медиа», 2013.
4. Sestini P, Cappiello V, Aliani M et al. Prescription bias and factors associated with improper use of inhalers.JAerosol Med, 2006, 19: 127-36.
5. James I. Therapeutic Respounses in Asthma and COPD. Bronchodilators. CHEST, 2004, 126: 125s-137s.
6. Шмелев Е.И. Амбулаторное лечение больных бронхиальной астмой и хронической обстркутивной болезнью легких (Результаты Всероссийской программы «СВОБОДА»). Consilium Medicum, 2007, 9: 58-63.
7. Будневский А.В. Сравнительная эффективность и безопасность р2-агонистов короткого действия на ранних стадиях ХОБЛ. Атмосфера. Пульмонология и аллергология, 2008, 1: 40-44.
Review
For citations:
Mescheryakova NN. Β2-agonist in patients with chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council. 2014;(4):25-27. (In Russ.)
Views:
437
Email this article 